Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developing guidelines for biotechnology drug use: experience with antithrombin III.

D R Romac1, P Poole, J T Owings

  • 1UC Davis Medical Center, Sacramento, CA 95817, USA.

Formulary (Cleveland, Ohio)
|August 6, 1995
PubMed
Summary

Developing institutional guidelines for high-cost biotechnology drugs like antithrombin III is key for formulary management. UC Davis Medical Center formed a committee to create evidence-based guidelines for optimal antithrombin III use.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of N-acetylcysteine dose for the treatment of massive acetaminophen ingestion.

Clinical toxicology (Philadelphia, Pa.)·2021
Same author

Age- and sex-appropriate cancer screening risks missing most occult malignancies in young patients with dermatomyositis.

The British journal of dermatology·2019
Same author

Why understanding the asthma chronic obstructive pulmonary disease overlap syndrome (ACOS) is important to the clinician.

The Indian journal of medical research·2016
Same author

Microengineering Laser Plasma Interactions at Relativistic Intensities.

Physical review letters·2016
Same author

An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System.

Human & experimental toxicology·2015
Same author

Author reply: To PMID 24863137.

Internal medicine journal·2015

Area of Science:

  • Pharmacoeconomics
  • Health policy
  • Biotechnology drug management

Background:

  • High-cost biotechnology drugs require careful formulary management.
  • Antithrombin III is a key example of a high-cost biotechnology agent.
  • Institutional guidelines aid in the optimal use of such therapies.

Purpose of the Study:

  • To describe the process of developing institutional guidelines for antithrombin III use.
  • To highlight the role of ad hoc committees in guideline development.
  • To emphasize the importance of literature analysis in creating consensus guidelines.

Main Methods:

  • Formation of an ad hoc committee reporting to the Pharmacy & Therapeutics (P&T) Committee.
  • Objective analysis of available scientific literature.

Related Experiment Videos

  • Development of consensus-based use guidelines.

    • Main Results:

    • Established a structured process for guideline creation.
    • Utilized literature review to define the role of antithrombin III.
    • Achieved P&T Committee approval for the developed guidelines.

    Conclusions:

    • Institutional guidelines are essential for managing high-cost biotechnology drugs.
    • A systematic approach involving literature review and committee approval ensures optimal drug utilization.
    • The process used at UC Davis Medical Center provides a model for other institutions.